Back to discover
Drug

Camostat

Approved medicine
ResearchOngoing clinical research

Also known as Camostatum.

RxNorm53141ChEMBLCHEMBL590799ATCB02AB04UNII0FD207WKDU
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Clinical trial2024-08-02Results posted · ClinicalTrials.gov

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.

Research2023-10-01Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19

Clinical trial2023-06-28Results posted · ClinicalTrials.gov

The DAWN Antivirals Trial: the Efficacy of Antivirals for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial

Clinical trial2022-07-13Terminated · ClinicalTrials.gov

The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

Clinical trial2022-07-12Terminated · ClinicalTrials.gov

COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19

Clinical trial2022-03-04Terminated · ClinicalTrials.gov

A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.

Clinical trial2022-03-03Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Camostat
Aliases & brands
Camostatum
RxNorm CUI
53141
ChEMBL ID
CHEMBL590799
ATC codes
B02AB04
UNII
0FD207WKDU

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
6
registered trials across all phases
LATEST COMPLETION 2023
2
Late-stage (III+)
2
Completed
4
Discontinued
PHASE DISTRIBUTIONn = 6
Phase 24Phase 2 / 31Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

CompletedPH II/IIIKey trialNational Institute of Allergy and Infectious Diseases (NIAID)n=4,0442023

The DAWN Antivirals Trial: the Efficacy of Antivirals for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial

TerminatedPH IIIKU Leuvenn=442022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023 · 17 cites
Recent papers

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023 · 17 cites
Major research themes1
COVID-191
Journals, researchers & institutions
Top journals
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
Leading researchers
  • Chew KW1
  • Coombs RW1
  • Currier JS1
  • Daar ES1
  • Eron JJ1
  • Giganti MJ1
  • Greninger AL1
  • Hart PA1
Leading institutions
free-text, unnormalised
  • Brigham and Women's Hospital1
  • Harvard T.H. Chan School of Public Health1
  • Massachusetts General Hospital and Department of Medicine1
  • Miami Clinical Research1
  • National Institutes of Health1
  • Quantum Clinical Trials1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials